Latest news and insights on the pharmaceutical industry | Indian Pharma Post
Diagnostic Center
Diagnostic Center | 25 May 2024

Zydus announces completion of Enrolment for Phase II clinical trial of Usnoflast

ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset

Diagnostic Center
Diagnostic Center | 21 May 2024

Dupixent late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD

Diagnostic Center
Diagnostic Center | 21 May 2024

Modular ATP study of the mCRM System meets primary safety and efficacy endpoints

Additional data from APPRAISE ATP trial reinforce modular therapy approach

Diagnostic Center
Diagnostic Center | 20 May 2024

Supernova Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19

SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients

Diagnostic Center
Diagnostic Center | 20 May 2024

Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi approved by USFDA

95.7% of patients responded to Breyanzi in the TRANSCEND FL trial

Diagnostic Center
Diagnostic Center | 18 May 2024

Arvinas and Pfizer announce updated clinical data from Phase 1b Trial of Vepdegestrant in combination with Palbociclib

At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months

Diagnostic Center
Diagnostic Center | 17 May 2024

Elinzanetant significantly reduces frequency and severity of hot flashes associated with menopause

Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms

Diagnostic Center
Diagnostic Center | 16 May 2024

Bayer starts Phase I study with novel targeted radionuclide therapy in advanced metastatic prostate cancer

225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer

Diagnostic Center
Diagnostic Center | 14 May 2024

Merck discontinues Phase 3 KeyVibe-010 trial of coformulation of Vibostolimab and Pembrolizumab

Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria

Diagnostic Center
Diagnostic Center | 08 May 2024

AstraZeneca’s Calquence combination regimen demonstrated positive results in 1st-line mantle cell lymphoma in ECHO Phase III trial

First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting

Diagnostic Center
Diagnostic Center | 02 May 2024

Merck announces positive data for investigational, 21-Valent pneumococcal conjugate vaccine

Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases

Diagnostic Center
Diagnostic Center | 02 May 2024

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024

New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD

Diagnostic Center
Diagnostic Center | 01 May 2024

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data

The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg

Diagnostic Center
Diagnostic Center | 17 April 2024

AbbVie announces late-breaking data at AAN supporting efficacy of Atogepant for preventive treatment of migraine

Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine

Diagnostic Center
Diagnostic Center | 17 April 2024

AstraZeneca’s Imfinzi plus chemotherapy doubled overall survival rate for patients with advanced biliary tract cancer

Longest survival follow-up ever reported for immunotherapy treatment in this setting

Diagnostic Center
Diagnostic Center | 16 April 2024

Novartis reports data from trial of IgA nephropathy treatment

IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide

Diagnostic Center
Diagnostic Center | 16 April 2024

Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024

Global Phase-3 study initiation expected in the second half of 2024

Diagnostic Center
Diagnostic Center | 15 April 2024

Teva confirms efficacy and safety of Ajovy for prevention of migraine

Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month

Diagnostic Center
Diagnostic Center | 12 April 2024

Pfizer announces positive results from Phase 3 Study of Abrysvo

ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.

Diagnostic Center
Diagnostic Center | 11 April 2024

KRAZATI in Combination with Cetuximab demonstrates targeted treatment option for KRAS G12C- colorectal cancer

Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program

Startup

Digitization